Formal Method Validation - The development and optimization process can improve a method, but validation does not. Validation is the final proof that regulations and expectations are met. - BioPharm


Formal Method Validation
The development and optimization process can improve a method, but validation does not. Validation is the final proof that regulations and expectations are met.

BioPharm International

AMV Acceptance Criteria

In-process and product specifications should be based on analytical capability.8 The mirror image must also be considered—AMV acceptance criteria must be related to specifications—because the observed process variability is the sum of actual process variability, test method variability, and sampling variability as illustrated in Equation 1 below.

[observed process variability] 2 =
[actual process variability] 2 +
[test method variability] 2 +
[sampling variability] 2

Known values for the observed (measured) process variability, the test method variability (intermediate precision), and sampling (batch uniformity as measured) variability can be used to estimate actual process variability and vice versa. For example, when the observed process variability is 10%, the method intermediate precision is 8%, and the sampling variability is 0% or negligible, the actual process variability is approximately 6%.

(0.10) 2 = X 2 + (0.08) 2
Solved: X = 0.06

Figure 1 illustrates which data sources should be evaluated for a new method and new drug product with an understanding that sometimes only reliable estimates for process variability and method variability may exist at the time of AMV studies. Naturally, the (target) specifications are pushing the acceptance criteria towards less risk (narrow limits) for the patient, while actual process, sampling and method performance imperfections push from the opposite side towards wider limits. Once we have estimates for each source of variation we can then set balanced expectations that can protect the patient (and firm). Simply put, the less data sources are available or evaluated, the more "gambling" will occur, because of the existing uncertainty, when setting AMV protocol acceptance criteria. The less method performance requirements are understood, the less predictable will be the understanding of the potential impact thus leading to greater risks to patients and the firm.6 When deriving acceptance criteria, balanced limits for the AMV protocol for accuracy, precision, and other assay characteristics can be derived from the specifications (or target specifications) and historical data sources. Clearly, if the specifications are not established, the method cannot be fully validated. Ultimately, we need balanced criteria that challenge the new method's ability to assure product quality with the need to formally validate the new method.6


1. International Conference on Harmonization. Q2(R1), Validation of analytical procedures. Current Step 4 Version. Geneva, Switzerland; 2005.

2. Eurachem Guide. Fitness for Purpose of Analytical Methods. Teddington, UK; 1998.

3. Center for Drug Evaluation and Research. Guidance for Industry. Bioanalytical method validation. Bethesda, MD; 2001.

4. Center for Biologics Evaluation and Research. Draft Guidance for Industry. Analytical procedures and methods validation. Bethesda, MD; 2000.

5. Krause SO. Development and validation of analytical methods for biopharma-ceuticals, part I: development and optimization. BioPharm Intl. 2004; 16(10):52–61.

6. Krause SO. Validation of analytical methods for biopharmaceuticals–a guide to risk based validation and implementation strategies. PDA/DHI Publishing. Bethesda, MD. 2007.

7. EURACHEM/CITAC Guide CG4, Tracebility in Chemical Measurements; 2003.

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here